Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 7;91(3):e2020026.
doi: 10.23750/abm.v91i3.10063.

A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand

Vincenzo De Sanctis  1 , Duran Canatan  2 , Joan Lluis Vives Corrons  3 , Mehran Karimi  4 , Shahina Daar  5 , Christos Kattamis  6 , Ashraf T Soliman  7 , Yasser Wali  8 , Salam Alkindi  5 , Valeh Huseynov  9 , Afag Nasibova  9 , Tarık Onur Tiryaki  10 , Melike Sezgin Evim  11 , Adalet Meral Gunes  11 , Zeynep Karakas  12 , Soteroula Christou  13 , Mohamed A Yassin  14 , Maria Concetta Galati  15 , Saveria Campisi  16 , Tahereh Zarei  4 , Doaa Khater  17 , Yesim Oymak  18 , Valeriya Kaleva  19 , Denka Stoyanova  20 , Atanas Banchev  20 , Myrto Skafida  6 , Yurdanur Kilinc  21
Affiliations
Review

A comprehensive update of ICET-A Network on COVID-19 in thalassemias: what we know and where we stand

Vincenzo De Sanctis et al. Acta Biomed. .

Abstract

A review of the literature on COVID-19 pandemic in patients with thalassemias is presented. Globally, the prevalence of COVID-19 among β-thalassemia patients seems to be lower than in general population; associated co-morbidities aggravated the severity of COVID- 19, leading to a poorer prognosis, irrespective of age. A multicenter registry will enhance the understanding of COVID-19 in these patients and will lead to more evidence-based management recommendations.

PubMed Disclaimer

Conflict of interest statement

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

    1. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11. Published 2010 May 21. doi:10.1186/1750-1172-5-11. - PMC - PubMed
    1. De Sanctis V, Kattamis C, Canatan D, et al. β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. Mediterr J Hematol Infect Dis. 2017;9(1):e2017018. Published 2017 Feb 20. doi:10.4084/MJHID.2017.018. - PMC - PubMed
    1. Cappellini MD, Motta I. New therapeutic targets in transfusion-dependent and -independent thalassemia. Hematology Am Soc Hematol Educ Program. 2017;1:278–283. - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. - PubMed
    1. Eleftheriou A. Thalassaemia & Sickle Cell Disease: Classification of Risk Groups & Other Considerations Guidance for Patients, Parents & Healthcare Professionals. 14 May 2020